Dechra has launched Pergocoat, a new treatment for pituitary pars intermedia dysfunction (PPID), otherwise known as equine Cushing’s disease.
Pergocoat contains pergolide as its active ingredient, a potent, long-acting dopamine receptor agonist and is available in both 0.5mg (off-white) and 1mg (yellow) tablets for accurate dosing without the need to split tablets. The tablets are film-coated to help mask the bitter taste of pergolide while also creating a barrier between the horse owner administering the treatment and the active ingredient.
Available in two different pack sizes containing 60 or 160 tablets, Pergocoat tablets are packaged in double-layered blister packs to help minimise the risk of accidental ingestion.
“Every horse is unique, and so is every PPID case, as horses differ in size and often have an individual response to treatment,” comments Rachel Addison, BVM&S MRCVS, equine field support manager at Dechra. “Pergocoat is available in two convenient tablet sizes for optimal treatment response. Horses can be monitored and reviewed every four to six weeks until stabilisation or improvement of clinical signs is observed.”
Pergocoat is Dechra’s first equine endocrinology product to join its extensive equine portfolio; however, the company is already known for expertise in endocrinology as it markets Vetoryl, the only licensed treatment for canine hyperadrenocorticism (Cushing’s syndrome) in dogs.
For further information on Pergocoat, please contact your local Dechra territory sales manager or visit the website.
